Phreesia, Inc. (NYSE:PHR) Stock Position Reduced by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. reduced its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 72.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,263 shares of the company's stock after selling 30,361 shares during the quarter. Balyasny Asset Management L.P.'s holdings in Phreesia were worth $283,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PHR. Greenhouse Funds LLLP lifted its position in shares of Phreesia by 27.9% in the fourth quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock valued at $72,307,000 after acquiring an additional 626,579 shares in the last quarter. Park West Asset Management LLC purchased a new stake in shares of Phreesia in the fourth quarter valued at $10,657,000. ExodusPoint Capital Management LP lifted its position in shares of Phreesia by 448.6% in the fourth quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after acquiring an additional 143,077 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its position in shares of Phreesia by 41.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 484,617 shares of the company's stock valued at $12,193,000 after acquiring an additional 141,411 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Phreesia by 120.4% in the fourth quarter. Barclays PLC now owns 209,209 shares of the company's stock valued at $5,264,000 after acquiring an additional 114,280 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Phreesia news, insider Yvonne Hui sold 1,878 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $23.85, for a total transaction of $44,790.30. Following the completion of the sale, the insider now owns 28,449 shares in the company, valued at $678,508.65. This trade represents a 6.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,213 shares of Phreesia stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total value of $28,881.53. Following the sale, the general counsel now owns 137,921 shares in the company, valued at $3,283,899.01. This represents a 0.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,474 shares of company stock worth $1,023,208. 5.80% of the stock is currently owned by corporate insiders.

Phreesia Trading Down 1.1%

NYSE:PHR traded down $0.27 on Friday, hitting $24.07. 242,602 shares of the stock were exchanged, compared to its average volume of 438,719. The stock has a market cap of $1.43 billion, a PE ratio of -16.37 and a beta of 0.74. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average of $25.18 and a 200-day moving average of $25.16. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53.

Wall Street Analyst Weigh In

PHR has been the subject of several analyst reports. KeyCorp dropped their target price on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, March 13th. DA Davidson dropped their target price on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Canaccord Genuity Group upped their target price on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, March 13th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $33.00 target price (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.